FDA's Latest Guide: Drug Safety Reports, Now with Timely Clarity
Published Date: 12/16/2025
Notice
Summary
The FDA just released final rules to help drug study sponsors keep safety reports clear and on time for new drug and bioequivalence studies. If you’re running these studies, you’ll need to follow these updated safety reporting steps starting now to avoid delays or extra costs. This guidance makes safety checks easier and keeps everyone on the same page for safer medicines.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Final guidance for IND safety reporting
If you run investigational new drug (IND) studies or IND‑exempt bioavailability/bioequivalence (BA/BE) studies, FDA issued a final guidance on December 16, 2025 with recommendations to help sponsors and sponsor‑investigators comply with expedited IND safety reporting (see 21 CFR 312.32 and 21 CFR 320.31(d)(3)). The guidance finalizes the June 28, 2021 draft and consolidates prior guidance to clarify sponsors' safety reporting responsibilities.
Revised aggregate analyses and rare disease guidance
The final guidance revises recommended approaches for aggregate analyses to reduce the need for unblinding when evaluating safety data. It also adds additional considerations specifically for small programs and rare disease studies.
Updated electronic submission information
The guidance provides updated information on electronic submission of IND safety reports, including references to electronic submission pathways such as the Electronic Submission Gateway and the Safety Reporting Portal. Related collections of information cited in the notice are approved under OMB control number 0910-0291.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-22869, Investigator Responsibilities-Safety Reporting for Investigational Drugs and Devices; Guidance for Investigators, Industry, and Institutional Review Boards; Availability
The FDA just released final guidance to help researchers safely report problems with new drugs and devices during studies. This update affects clinical investigators, companies, and review boards by clarifying what safety info must be shared and when. The guidance is effective now, aiming to keep everyone on the same page without adding extra costs or delays.
Next: 2025-22871, Sunshine Act Meetings
The National Credit Union Administration is holding an open meeting on December 18, 2025, to talk about the Share Insurance Fund and the 2026-2027 budget. Credit unions and the public get a clear look at how money is managed and planned. This meeting keeps things transparent and on track for the coming years without any new costs announced.